GDF15-GFRAL Pathway Modulation for Refractory Nausea and Emesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for nausea and emesis, particularly in conditions like Hyperemesis Gravidarum (HG), Cyclic Vomiting Syndrome (CVS), Cannabinoid Hyperemesis Syndrome (CHS), Mitochondrial Disorders (MIDs), and Migraine Associated Nausea/Vomiting (MAN/V), are inadequate, and there is a need for effective therapies targeting the GDF15-GFRAL pathway.
Innovation Solution
Administration of a GDF15-GFRAL Pathway Modulating Agent, such as a GDF15 Antibody Agent or a GFRAL Antibody Agent, to reduce the activity of the GDF15-GFRAL pathway, thereby alleviating symptoms of nausea and emesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for nausea and emesis are used, then treatment coverage is limited, but the need for effective therapies remains unmet
Solution Approach 1:
The patent applies universality by developing a therapeutic approach targeting the GDF15-GFRAL pathway that can treat multiple types of nausea and emesis across different medical conditions (hyperemesis gravidarum, chemotherapy-induced, cyclic vomiting syndrome, etc.), rather than condition-specific treatments. This multi-functional approach addresses the unmet need for broader treatment coverage while maintaining effectiveness.
2Ease of operation
If GDF15-GFRAL pathway is targeted to reduce nausea and emesis, then symptom relief is achieved, but the mechanism requires new therapeutic agents
Solution Approach 1:
The patent uses antibodies as intermediary molecules that specifically bind to and modulate the GDF15-GFRAL pathway. These antibody intermediaries translate the biological mechanism into a clinically applicable therapy, providing symptom relief while the manufacturing challenges are addressed through standardized antibody production methods.
Data Source
AI summary
Provided herein are methods of treating and/or preventing certain types and/or instances of nausea and/or emesis with which it had not previously been considered to be associated, by targeting the GDF15-GFRAL pathway.